sny-20220630假象0001121404--12-316/30/20222022Q20.043478260869565200011214042022-01-012022-06-3000011214042022-06-30ISO4217：欧元00011214042021-12-3100011214042021-01-012021-06-3000011214042021-01-012021-12-31Xbrli：共享ISO4217：欧元Xbrli：共享0001121404IFRS-Full：IssuedCapitalMembers2019-12-310001121404IFRS-FULL：AdditionalPidinCapitalMembers2019-12-310001121404IFRS-Full：财务份额成员2019-12-310001121404IFRS-Full：RetainedEarningsMembers2019-12-310001121404IFRS-FULL：基于共享的预留付款成员2019-12-310001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMember2019-12-310001121404Ifrs-full:EquityAttributableToOwnersOfParentMember2019-12-310001121404IFRS-FULL：非控制性利益成员2019-12-3100011214042019-12-310001121404IFRS-Full：RetainedEarningsMembers2020-01-012020-12-310001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310001121404Ifrs-full:EquityAttributableToOwnersOfParentMember2020-01-012020-12-310001121404IFRS-FULL：非控制性利益成员2020-01-012020-12-3100011214042020-01-012020-12-310001121404IFRS-Full：财务份额成员2020-01-012020-12-310001121404IFRS-Full：IssuedCapitalMembers2020-01-012020-12-310001121404IFRS-FULL：AdditionalPidinCapitalMembers2020-01-012020-12-310001121404IFRS-FULL：基于共享的预留付款成员2020-01-012020-12-310001121404IFRS-Full：IssuedCapitalMembers2020-12-310001121404IFRS-FULL：AdditionalPidinCapitalMembers2020-12-310001121404IFRS-Full：财务份额成员2020-12-310001121404IFRS-Full：RetainedEarningsMembers2020-12-310001121404IFRS-FULL：基于共享的预留付款成员2020-12-310001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMember2020-12-310001121404Ifrs-full:EquityAttributableToOwnersOfParentMember2020-12-310001121404IFRS-FULL：非控制性利益成员2020-12-3100011214042020-12-310001121404IFRS-Full：RetainedEarningsMembers2021-01-012021-06-300001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-06-300001121404Ifrs-full:EquityAttributableToOwnersOfParentMember2021-01-012021-06-300001121404IFRS-FULL：非控制性利益成员2021-01-012021-06-300001121404IFRS-Full：财务份额成员2021-01-012021-06-300001121404IFRS-FULL：AdditionalPidinCapitalMembers2021-01-012021-06-300001121404IFRS-Full：IssuedCapitalMembers2021-01-012021-06-300001121404IFRS-FULL：基于共享的预留付款成员2021-01-012021-06-300001121404IFRS-Full：IssuedCapitalMembers2021-06-300001121404IFRS-FULL：AdditionalPidinCapitalMembers2021-06-300001121404IFRS-Full：财务份额成员2021-06-300001121404IFRS-Full：RetainedEarningsMembers2021-06-300001121404IFRS-FULL：基于共享的预留付款成员2021-06-300001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMember2021-06-300001121404Ifrs-full:EquityAttributableToOwnersOfParentMember2021-06-300001121404IFRS-FULL：非控制性利益成员2021-06-3000011214042021-06-300001121404IFRS-Full：RetainedEarningsMembers2021-07-012021-12-310001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-12-310001121404Ifrs-full:EquityAttributableToOwnersOfParentMember2021-07-012021-12-310001121404IFRS-FULL：非控制性利益成员2021-07-012021-12-3100011214042021-07-012021-12-310001121404IFRS-Full：财务份额成员2021-07-012021-12-310001121404IFRS-FULL：AdditionalPidinCapitalMembers2021-07-012021-12-310001121404IFRS-Full：IssuedCapitalMembers2021-07-012021-12-310001121404IFRS-FULL：基于共享的预留付款成员2021-07-012021-12-310001121404IFRS-Full：IssuedCapitalMembers2021-12-310001121404IFRS-FULL：AdditionalPidinCapitalMembers2021-12-310001121404IFRS-Full：财务份额成员2021-12-310001121404IFRS-Full：RetainedEarningsMembers2021-12-310001121404IFRS-FULL：基于共享的预留付款成员2021-12-310001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMember2021-12-310001121404Ifrs-full:EquityAttributableToOwnersOfParentMember2021-12-310001121404IFRS-FULL：非控制性利益成员2021-12-310001121404IFRS-Full：RetainedEarningsMembers2022-01-012022-06-300001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-06-300001121404Ifrs-full:EquityAttributableToOwnersOfParentMember2022-01-012022-06-300001121404IFRS-FULL：非控制性利益成员2022-01-012022-06-300001121404SNY：Euroapi成员2022-01-012022-06-30Xbrli：纯0001121404IFRS-Full：财务份额成员2022-01-012022-06-300001121404IFRS-Full：IssuedCapitalMembers2022-01-012022-06-300001121404IFRS-FULL：AdditionalPidinCapitalMembers2022-01-012022-06-300001121404IFRS-FULL：基于共享的预留付款成员2022-01-012022-06-300001121404IFRS-Full：IssuedCapitalMembers2022-06-300001121404IFRS-FULL：AdditionalPidinCapitalMembers2022-06-300001121404IFRS-Full：财务份额成员2022-06-300001121404IFRS-Full：RetainedEarningsMembers2022-06-300001121404IFRS-FULL：基于共享的预留付款成员2022-06-300001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMember2022-06-300001121404Ifrs-full:EquityAttributableToOwnersOfParentMember2022-06-300001121404IFRS-FULL：非控制性利益成员2022-06-300001121404SNY：Euroapi成员2022-05-102022-05-100001121404Sny:ConsumerHealthcareAndPharmaceuticalsMember2022-01-012022-06-30SNY：活动0001121404SNY：制药公司成员2021-01-012021-06-300001121404SNY：制药公司成员2021-01-012021-12-310001121404SNY：Consumer Healthcare成员2021-01-012021-12-310001121404国家/地区：AR2022-06-300001121404国家/地区：tr2022-06-3000011214042022-06-13SNY：试用版0001121404SNY：美国政府成员SNY：与GSK成员协作协议2022-01-012022-06-300001121404SNY：美国政府成员SNY：与GSK成员协作协议2021-01-012021-12-310001121404SNY：Amunix PharmPharmticalsIncMember2022-02-08ISO 4217：美元0001121404SNY：Amunix PharmPharmticalsIncMember2022-02-082022-06-300001121404SNY：Euroapi成员2022-03-172022-03-170001121404SNY：EPICBPIFranceMemberSNY：Euroapi成员2022-03-170001121404SNY：EPICBPIFranceMemberSNY：Euroapi成员2022-03-172022-03-170001121404SNY：Euroapi成员2022-05-102022-06-300001121404SNY：Euroapi成员2022-05-102022-05-100001121404SNY：Euroapi成员2022-05-032022-05-030001121404SNY：Euroapi成员2022-05-100001121404SNY：Euroapi成员2021-01-012021-12-310001121404SNY：EPICBPIFranceMemberSNY：Euroapi成员2022-06-172022-06-170001121404SNY：EPICBPIFranceMemberSNY：Euroapi成员2022-06-170001121404SNY：Euroapi成员2022-06-300001121404Ifrs-full:ProvisionForDecommissioningRestorationAndRehabilitationCostsMember2022-05-100001121404SNY：监管合规性成本成员2022-05-100001121404SNY：Euroapi成员Sny:ManufactureAndSupplyCollaborationAgreementMember2021-10-012021-10-010001121404SNY：Euroapi成员Sny:ManufactureAndSupplyCollaborationAgreementMember2021-10-010001121404SNY：Euroapi成员Sny:ManufactureAndSupplyCollaborationAgreementMember2022-06-300001121404SNY：主要协作协议成员Sny:ImmunoOncologyCollaborationAgreementMemberSNY：更新换代制药公司成员2022-07-012022-07-310001121404Sny:ImmunoOncologyCollaborationAgreementMemberSNY：更新换代制药公司成员2022-06-012022-06-300001121404SNY：更新换代制药公司成员2022-06-300001121404SNY：抗体协作协议成员SNY：更新换代制药公司成员2022-01-012022-05-310001121404SNY：抗体协作协议成员SNY：更新换代制药公司成员2022-06-012022-06-300001121404SNY：抗体协作协议成员SNY：更新换代制药公司成员2022-01-012022-06-300001121404SNY：制药公司成员2022-01-012022-06-300001121404SNY：制药公司成员2021-01-012021-12-310001121404SNY：制药公司成员SNY：IndustrialFacilities成员2022-01-012022-06-300001121404SNY：制药公司成员SNY：IndustrialFacilities成员2021-01-012021-12-310001121404SNY：制药公司成员SNY：研究站点成员2022-01-012022-06-300001121404SNY：制药公司成员SNY：研究站点成员2021-01-012021-12-310001121404SNY：制药公司成员SNY：其他成员2022-01-012022-06-300001121404SNY：制药公司成员SNY：其他成员2021-01-012021-12-310001121404SNY：疫苗成员2022-01-012022-06-300001121404SNY：疫苗成员2021-01-012021-12-310001121404SNY：Consumer Healthcare成员2022-01-012022-06-300001121404SNY：Consumer Healthcare成员2021-01-012021-12-310001121404SNY：获取的RAND成员IFRS-Full：Gross CarryingAmount Member2021-12-310001121404Sny:MarketedProductsTrademarksAndOtherRightsMemberIFRS-Full：Gross CarryingAmount Member2021-12-310001121404IFRS-FULL：计算机软件成员IFRS-Full：Gross CarryingAmount Member2021-12-310001121404IFRS-Full：Gross CarryingAmount Member2021-12-310001121404SNY：获取的RAND成员IFRS-Full：Gross CarryingAmount Member2022-01-012022-06-300001121404Sny:MarketedProductsTrademarksAndOtherRightsMemberIFRS-Full：Gross CarryingAmount Member2022-01-012022-06-300001121404IFRS-FULL：计算机软件成员IFRS-Full：Gross CarryingAmount Member2022-01-012022-06-300001121404IFRS-Full：Gross CarryingAmount Member2022-01-012022-06-300001121404SNY：获取的RAND成员IFRS-Full：Gross CarryingAmount Member2022-06-300001121404Sny:MarketedProductsTrademarksAndOtherRightsMemberIFRS-Full：Gross CarryingAmount Member2022-06-300001121404IFRS-FULL：计算机软件成员IFRS-Full：Gross CarryingAmount Member2022-06-300001121404IFRS-Full：Gross CarryingAmount Member2022-06-300001121404SNY：获取的RAND成员Ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2021-12-310001121404Sny:MarketedProductsTrademarksAndOtherRightsMemberIfrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2021-12-310001121404IFRS-FULL：计算机软件成员Ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2021-12-310001121404Ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2021-12-310001121404SNY：获取的RAND成员Ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-01-012022-06-300001121404Sny:MarketedProductsTrademarksAndOtherRightsMemberIfrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-01-012022-06-300001121404IFRS-FULL：计算机软件成员Ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-01-012022-06-300001121404Ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-01-012022-06-300001121404SNY：获取的RAND成员Ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-06-300001121404Sny:MarketedProductsTrademarksAndOtherRightsMemberIfrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-06-300001121404IFRS-FULL：计算机软件成员Ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-06-300001121404Ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-06-300001121404SNY：获取的RAND成员2021-12-310001121404Sny:MarketedProductsTrademarksAndOtherRightsMember2021-12-310001121404IFRS-FULL：计算机软件成员2021-12-310001121404SNY：获取的RAND成员2022-06-300001121404Sny:MarketedProductsTrademarksAndOtherRightsMember2022-06-300001121404IFRS-FULL：计算机软件成员2022-06-300001121404SNY：Amunix PharmPharmticalsIncMemberSny:MarketedProductsTrademarksAndOtherRightsMemberIFRS-Full：Gross CarryingAmount Member2022-01-012022-06-300001121404SNY：LibtayoMembersIFRS-FULL：非当前资产HeldForSaleMemberIFRS-Full：Gross CarryingAmount Member2022-06-300001121404SNY：LibtayoMembersIFRS-FULL：非当前资产HeldForSaleMemberIfrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-06-300001121404SNY：EnjaymoMembers2022-01-012022-06-300001121404SNY：EnjaymoMembersIFRS-Full：Gross CarryingAmount Member2022-01-012022-06-300001121404SNY：EnjaymoMembersIfrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-01-012022-06-300001121404SNY：技术平台成员2022-01-012022-06-300001121404Sny:OtherIntangibleAssetsExcludingSoftwareMember2022-01-012022-06-300001121404SNY：市场化产品成员2022-06-300001121404SNY：市场化产品成员2021-12-310001121404SNY：市场化产品成员2022-01-012022-06-300001121404SNY：技术平台成员2022-06-300001121404SNY：技术平台成员2021-12-310001121404SNY：Euroapi成员2022-01-012022-06-300001121404SNY：Euroapi成员2021-12-310001121404SNY：InfraservGmbhAndCoHochstKGMember2022-01-012022-06-300001121404SNY：InfraservGmbhAndCoHochstKGMember2022-06-300001121404SNY：InfraservGmbhAndCoHochstKGMember2021-12-310001121404SNY：MSPVaccineCompany成员2022-01-012022-06-300001121404SNY：MSPVaccineCompany成员2022-06-300001121404SNY：MSPVaccineCompany成员2021-12-310001121404Ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember2022-01-012022-06-300001121404Ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember2022-06-300001121404Ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember2021-12-310001121404SNY：MCMVaccineBVMembersSNY：MSPVaccineCompany成员2022-01-012022-06-300001121404SNY：AssociatesAndJointVenturesMembers2022-01-012022-06-300001121404SNY：AssociatesAndJointVenturesMembers2021-01-012021-06-300001121404SNY：AssociatesAndJointVenturesMembers2021-01-012021-12-310001121404SNY：AssociatesAndJointVenturesMembers2022-06-300001121404SNY：AssociatesAndJointVenturesMembers2021-06-300001121404SNY：AssociatesAndJointVenturesMembers2021-12-310001121404IFRS-Full：TradingEquitySecuritiesMembers2022-06-300001121404IFRS-Full：TradingEquitySecuritiesMembers2021-12-310001121404IFRS-Full：债务证券成员2022-06-300001121404IFRS-Full：债务证券成员2021-12-310001121404SNY：ExScience成员2022-01-072022-01-070001121404SNY：IGM BiosciencesIncMember2022-03-292022-03-290001121404IFRS-FULL：AllowanceForCreditLosesMember2022-06-300001121404IFRS-FULL：AllowanceForCreditLosesMember2021-12-310001121404IFRS-Full：非晚于一个月成员2022-06-300001121404Ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember2022-06-300001121404Ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember2022-06-300001121404Ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember2022-06-300001121404IFRS-Full：晚于一年成员2022-06-300001121404IFRS-Full：非晚于一个月成员2021-12-310001121404Ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember2021-12-310001121404Ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember2021-12-310001121404Ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember2021-12-310001121404IFRS-Full：晚于一年成员2021-12-310001121404IFRS-Full：IssuedCapitalMembers纽约：SanofiMembers2022-01-012022-06-300001121404SNY：共享回购2021计划成员2021-04-302021-04-300001121404SNY：共享回购2021计划成员2021-01-012021-06-300001121404SNY：共享回购2021计划成员2021-06-300001121404SNY：共享回购2022计划成员2022-05-032022-05-030001121404SNY：受限共享计划2022成员2022-01-012022-06-300001121404SNY：受限共享计划2022成员SNY：无市场条件成员2022-01-012022-06-300001121404SNY：具有市场条件成员SNY：受限共享计划2022成员2022-01-012022-06-300001121404SNY：具有市场条件成员SNY：受限共享计划2022成员SNY：排除首席执行官ExecutiveOfficerMember2022-01-012022-06-300001121404SNY：具有市场条件成员Sny:RestrictedSharePlan2022AdditionalSharesMemberSNY：排除首席执行官ExecutiveOfficerMember2022-01-012022-06-300001121404SNY：具有市场条件成员SNY：受限共享计划2022成员SRT：首席执行官执行官员成员2022-01-012022-06-300001121404SNY：受限共享成员2022-01-012022-06-300001121404SNY：受限共享成员2021-01-012021-06-300001121404SNY：受限共享成员2022-06-300001121404SNY：受限共享成员2021-06-300001121404SNY：受限共享计划2022成员2022-06-300001121404SNY：受限共享计划2022成员2021-06-300001121404SNY：受限共享计划2021成员2022-06-300001121404SNY：受限共享计划2021成员2021-06-300001121404SNY：受限共享计划2020成员2022-06-300001121404SNY：受限共享计划2020成员2021-06-300001121404SNY：受限共享计划2019年成员2022-06-300001121404SNY：受限共享计划2019年成员2021-06-300001121404SNY：受限共享计划2018年成员2022-06-300001121404SNY：受限共享计划2018年成员2021-06-300001121404SNY：EmployeeShareOwnership PlanMember2022-02-030001121404SNY：EmployeeShareOwnership PlanMember2022-06-290001121404SNY：EmployeeShareOwnership PlanMember2022-01-012022-06-300001121404SNY：EmployeeShareOwnership PlanMember2021-02-040001121404SNY：EmployeeShareOwnership PlanMember2021-06-250001121404SNY：EmployeeShareOwnership PlanMember2021-01-012021-06-300001121404IFRS-FULL：底部范围成员SNY：股票选项计划成员SNY：ExercisePriceRange两成员2022-06-300001121404SNY：股票选项计划成员IFRS-Full：TopOfRangeMemberSNY：ExercisePriceRange两成员2022-06-300001121404SNY：股票选项计划成员SNY：ExercisePriceRange两成员2022-06-300001121404SNY：股票选项计划成员SNY：ExercisePriceRange两成员2022-01-012022-06-300001121404IFRS-FULL：底部范围成员SNY：股票选项计划成员SNY：练习PriceRange3成员2022-06-300001121404SNY：股票选项计划成员IFRS-Full：TopOfRangeMemberSNY：练习PriceRange3成员2022-06-300001121404SNY：股票选项计划成员SNY：练习PriceRange3成员2022-06-300001121404SNY：股票选项计划成员SNY：练习PriceRange3成员2022-01-012022-06-300001121404SNY：ExercisePriceRange4成员IFRS-FULL：底部范围成员SNY：股票选项计划成员2022-06-300001121404SNY：ExercisePriceRange4成员SNY：股票选项计划成员IFRS-Full：TopOfRangeMember2022-06-300001121404SNY：ExercisePriceRange4成员SNY：股票选项计划成员2022-06-300001121404SNY：ExercisePriceRange4成员SNY：股票选项计划成员2022-01-012022-06-300001121404SNY：股票选项计划成员2022-06-300001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMemberSny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember2022-01-012022-06-300001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMemberSny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember2021-01-012021-06-300001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMemberSny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember2021-01-012021-12-310001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMemberSny:EquityInstrumentsIncludedInFinancialAssetsMemberSny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember2022-01-012022-06-300001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMemberSny:EquityInstrumentsIncludedInFinancialAssetsMemberSny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember2021-01-012021-06-300001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMemberSny:EquityInstrumentsIncludedInFinancialAssetsMemberSny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember2021-01-012021-12-310001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMemberSny:ItemsSubsequentlyReclassifiableToProfitOrLossMemberSNY：债务工具成员2022-01-012022-06-300001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMemberSny:ItemsSubsequentlyReclassifiableToProfitOrLossMemberSNY：债务工具成员2021-01-012021-06-300001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMemberSny:ItemsSubsequentlyReclassifiableToProfitOrLossMemberSNY：债务工具成员2021-01-012021-12-310001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMemberSny:ItemsSubsequentlyReclassifiableToProfitOrLossMember2022-01-012022-06-300001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMemberSny:ItemsSubsequentlyReclassifiableToProfitOrLossMember2021-01-012021-06-300001121404Ifrs-full:AccumulatedOtherComprehensiveIncomeMemberSny:ItemsSubsequentlyReclassifiableToProfitOrLossMember2021-01-012021-12-310001121404Sny:ItemsSubsequentlyReclassifiableToProfitOrLossMemberSNY：债务工具成员2022-01-012022-06-300001121404Sny:ItemsSubsequentlyReclassifiableToProfitOrLossMemberSNY：债务工具成员2021-01-012021-12-310001121404Sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember2022-01-012022-06-300001121404Sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember2021-01-012021-12-310001121404Sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember2021-01-012021-06-300001121404SNY：摊销成本净额成员2022-06-300001121404SNY：调整至负债测量属性公允价值成员2022-06-300001121404SNY：ValueOnRedemptionMember2022-06-300001121404SNY：ValueOnRedemptionMember2021-12-310001121404SNY：非当前责任成员SNY：ValueOnRedemptionMember2022-06-300001121404SNY：ValueOnRedemptionMemberSNY：当前责任成员2022-06-300001121404SNY：非当前责任成员SNY：ValueOnRedemptionMember2021-12-310001121404SNY：ValueOnRedemptionMemberSNY：当前责任成员2021-12-310001121404SNY：ValueOnRedemptionMemberSNY：非当前资产成员2022-06-300001121404SNY：ValueOnRedemptionMemberSNY：当前资产成员2022-06-300001121404SNY：ValueOnRedemptionMemberSNY：非当前资产成员2021-12-310001121404SNY：ValueOnRedemptionMemberSNY：当前资产成员2021-12-310001121404Sny:OneBillionFiveHundredMillionBondsIssuedInApril2022Member2022-04-30SNY：部分0001121404Sny:EightHundredAndFiftyMillionOfFixedRateBondsMaturingAprilTwoThousandTwentyFiveMember2022-04-300001121404Sny:SixHundredAndFiftyMillionOfFixedRateBondsMaturingAprilTwoThousandTwentyNineMember2022-04-30SNY：患者SNY：国家SNY：债券0001121404SNY：2022年1月到期的10亿债券2014-09-300001121404Sny:EightHundredFiftyMillionBondsMaturingFebruary2022Member2019-03-310001121404Sny:EightHundredFiftyMillionBondsMaturingJune2022Member2016-09-300001121404SNY：SyndicatedCreditFacilityOneMember2022-06-300001121404SNY：SyndicatedCreditFacilityTwoMember2022-06-300001121404SNY：SyndicatedCreditFacilityTwoMember2022-01-012022-06-300001121404SNY：法国商业纸业计划成员2022-06-300001121404SNY：美国商业纸张计划成员2022-06-300001121404SNY：美国商业纸张计划成员2022-01-012022-06-300001121404SNY：AtMarketValueMember2022-06-300001121404SNY：AtMarketValueMember2021-12-310001121404SNY：ValueOnRedemptionMember2022-01-012022-06-300001121404SNY：ValueOnRedemptionMember2021-01-012021-12-310001121404SNY：ForwardCurrencySalesMemberSNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberSNY：ForwardCurrencySalesMember2022-06-300001121404SNY：ForwardCurrencySalesMemberIFRS-Full：现金流量对冲成员SNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberSNY：ForwardCurrencySalesMemberIFRS-Full：现金流量对冲成员2022-06-300001121404SNY：ForwardCurrencySalesMemberIFRS-Full：现金流量对冲成员SNY：ValueOfHedgeRecognizedInEquityMember2022-06-300001121404SNY：ForwardCurrencySalesMemberSNY：NotEligibleForHedgeAccount成员SNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberSNY：ForwardCurrencySalesMemberSNY：NotEligibleForHedgeAccount成员2022-06-300001121404SNY：ForwardCurrencySalesInUSDollarMemberSNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberSNY：ForwardCurrencySalesInUSDollarMember2022-06-300001121404IFRS-Full：现金流量对冲成员SNY：ForwardCurrencySalesInUSDollarMemberSNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：现金流量对冲成员SNY：ForwardCurrencySalesInUSDollarMember2022-06-300001121404IFRS-Full：现金流量对冲成员SNY：ValueOfHedgeRecognizedInEquityMemberSNY：ForwardCurrencySalesInUSDollarMember2022-06-300001121404SNY：ForwardCurrencySalesInUSDollarMemberSNY：NotEligibleForHedgeAccount成员SNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberSNY：ForwardCurrencySalesInUSDollarMemberSNY：NotEligibleForHedgeAccount成员2022-06-300001121404SNY：AtNotionalAmount成员Sny:ForwardCurrencySalesInChineseYuanRenminbiMember2022-06-300001121404IFRS-Full：AtFairValueMemberSny:ForwardCurrencySalesInChineseYuanRenminbiMember2022-06-300001121404IFRS-Full：现金流量对冲成员SNY：AtNotionalAmount成员Sny:ForwardCurrencySalesInChineseYuanRenminbiMember2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：现金流量对冲成员Sny:ForwardCurrencySalesInChineseYuanRenminbiMember2022-06-300001121404IFRS-Full：现金流量对冲成员SNY：ValueOfHedgeRecognizedInEquityMemberSny:ForwardCurrencySalesInChineseYuanRenminbiMember2022-06-300001121404SNY：NotEligibleForHedgeAccount成员SNY：AtNotionalAmount成员Sny:ForwardCurrencySalesInChineseYuanRenminbiMember2022-06-300001121404IFRS-Full：AtFairValueMemberSNY：NotEligibleForHedgeAccount成员Sny:ForwardCurrencySalesInChineseYuanRenminbiMember2022-06-300001121404Sny:ForwardCurrencySalesInSingaporeDollarMemberSNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberSny:ForwardCurrencySalesInSingaporeDollarMember2022-06-300001121404IFRS-Full：现金流量对冲成员Sny:ForwardCurrencySalesInSingaporeDollarMemberSNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：现金流量对冲成员Sny:ForwardCurrencySalesInSingaporeDollarMember2022-06-300001121404IFRS-Full：现金流量对冲成员SNY：ValueOfHedgeRecognizedInEquityMemberSny:ForwardCurrencySalesInSingaporeDollarMember2022-06-300001121404Sny:ForwardCurrencySalesInSingaporeDollarMemberSNY：NotEligibleForHedgeAccount成员SNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberSny:ForwardCurrencySalesInSingaporeDollarMemberSNY：NotEligibleForHedgeAccount成员2022-06-300001121404SNY：ForwardCurrencySalesin Japan YenMemberSNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberSNY：ForwardCurrencySalesin Japan YenMember2022-06-300001121404IFRS-Full：现金流量对冲成员SNY：ForwardCurrencySalesin Japan YenMemberSNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：现金流量对冲成员SNY：ForwardCurrencySalesin Japan YenMember2022-06-300001121404IFRS-Full：现金流量对冲成员SNY：ForwardCurrencySalesin Japan YenMemberSNY：ValueOfHedgeRecognizedInEquityMember2022-06-300001121404SNY：ForwardCurrencySalesin Japan YenMemberSNY：NotEligibleForHedgeAccount成员SNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberSNY：ForwardCurrencySalesin Japan YenMemberSNY：NotEligibleForHedgeAccount成员2022-06-300001121404SNY：ForwardCurrencySalesin Korea WonMemberSNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberSNY：ForwardCurrencySalesin Korea WonMember2022-06-300001121404IFRS-Full：现金流量对冲成员SNY：ForwardCurrencySalesin Korea WonMemberSNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：现金流量对冲成员SNY：ForwardCurrencySalesin Korea WonMember2022-06-300001121404IFRS-Full：现金流量对冲成员SNY：ForwardCurrencySalesin Korea WonMemberSNY：ValueOfHedgeRecognizedInEquityMember2022-06-300001121404SNY：ForwardCurrencySalesin Korea WonMemberSNY：NotEligibleForHedgeAccount成员SNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberSNY：ForwardCurrencySalesin Korea WonMemberSNY：NotEligibleForHedgeAccount成员2022-06-300001121404SNY：远期现货采购成员SNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberSNY：远期现货采购成员2022-06-300001121404IFRS-Full：现金流量对冲成员SNY：远期现货采购成员SNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：现金流量对冲成员SNY：远期现货采购成员2022-06-300001121404IFRS-Full：现金流量对冲成员SNY：ValueOfHedgeRecognizedInEquityMemberSNY：远期现货采购成员2022-06-300001121404SNY：远期现货采购成员SNY：NotEligibleForHedgeAccount成员SNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberSNY：远期现货采购成员SNY：NotEligibleForHedgeAccount成员2022-06-300001121404SNY：远期现货购买量美元成员SNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberSNY：远期现货购买量美元成员2022-06-300001121404IFRS-Full：现金流量对冲成员SNY：远期现货购买量美元成员SNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：现金流量对冲成员SNY：远期现货购买量美元成员2022-06-300001121404IFRS-Full：现金流量对冲成员SNY：ValueOfHedgeRecognizedInEquityMemberSNY：远期现货购买量美元成员2022-06-300001121404SNY：远期现货购买量美元成员SNY：NotEligibleForHedgeAccount成员SNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberSNY：远期现货购买量美元成员SNY：NotEligibleForHedgeAccount成员2022-06-300001121404Sny:ForwardCurrencyPurchasesInSingaporeDollarMemberSNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberSny:ForwardCurrencyPurchasesInSingaporeDollarMember2022-06-300001121404IFRS-Full：现金流量对冲成员Sny:ForwardCurrencyPurchasesInSingaporeDollarMemberSNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：现金流量对冲成员Sny:ForwardCurrencyPurchasesInSingaporeDollarMember2022-06-300001121404IFRS-Full：现金流量对冲成员SNY：ValueOfHedgeRecognizedInEquityMemberSny:ForwardCurrencyPurchasesInSingaporeDollarMember2022-06-300001121404Sny:ForwardCurrencyPurchasesInSingaporeDollarMemberSNY：NotEligibleForHedgeAccount成员SNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberSny:ForwardCurrencyPurchasesInSingaporeDollarMemberSNY：NotEligibleForHedgeAccount成员2022-06-300001121404SNY：结转货币购买在韩国韩元成员SNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberSNY：结转货币购买在韩国韩元成员2022-06-300001121404IFRS-Full：现金流量对冲成员SNY：结转货币购买在韩国韩元成员SNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：现金流量对冲成员SNY：结转货币购买在韩国韩元成员2022-06-300001121404IFRS-Full：现金流量对冲成员SNY：ValueOfHedgeRecognizedInEquityMemberSNY：结转货币购买在韩国韩元成员2022-06-300001121404SNY：结转货币购买在韩国韩元成员SNY：NotEligibleForHedgeAccount成员SNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberSNY：结转货币购买在韩国韩元成员SNY：NotEligibleForHedgeAccount成员2022-06-300001121404SNY：AtNotionalAmount成员Sny:ForwardCurrencyPurchasesInCanadianDollarMember2022-06-300001121404IFRS-Full：AtFairValueMemberSny:ForwardCurrencyPurchasesInCanadianDollarMember2022-06-300001121404IFRS-Full：现金流量对冲成员SNY：AtNotionalAmount成员Sny:ForwardCurrencyPurchasesInCanadianDollarMember2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：现金流量对冲成员Sny:ForwardCurrencyPurchasesInCanadianDollarMember2022-06-300001121404IFRS-Full：现金流量对冲成员SNY：ValueOfHedgeRecognizedInEquityMemberSny:ForwardCurrencyPurchasesInCanadianDollarMember2022-06-300001121404SNY：NotEligibleForHedgeAccount成员SNY：AtNotionalAmount成员Sny:ForwardCurrencyPurchasesInCanadianDollarMember2022-06-300001121404IFRS-Full：AtFairValueMemberSNY：NotEligibleForHedgeAccount成员Sny:ForwardCurrencyPurchasesInCanadianDollarMember2022-06-300001121404SNY：AtNotionalAmount成员Sny:ForwardCurrencyPurchasesInJapaneseYenMember2022-06-300001121404IFRS-Full：AtFairValueMemberSny:ForwardCurrencyPurchasesInJapaneseYenMember2022-06-300001121404IFRS-Full：现金流量对冲成员SNY：AtNotionalAmount成员Sny:ForwardCurrencyPurchasesInJapaneseYenMember2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：现金流量对冲成员Sny:ForwardCurrencyPurchasesInJapaneseYenMember2022-06-300001121404IFRS-Full：现金流量对冲成员SNY：ValueOfHedgeRecognizedInEquityMemberSny:ForwardCurrencyPurchasesInJapaneseYenMember2022-06-300001121404SNY：NotEligibleForHedgeAccount成员SNY：AtNotionalAmount成员Sny:ForwardCurrencyPurchasesInJapaneseYenMember2022-06-300001121404IFRS-Full：AtFairValueMemberSNY：NotEligibleForHedgeAccount成员Sny:ForwardCurrencyPurchasesInJapaneseYenMember2022-06-300001121404SNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMember2022-06-300001121404IFRS-Full：现金流量对冲成员SNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：现金流量对冲成员2022-06-300001121404IFRS-Full：现金流量对冲成员SNY：ValueOfHedgeRecognizedInEquityMember2022-06-300001121404SNY：NotEligibleForHedgeAccount成员SNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberSNY：NotEligibleForHedgeAccount成员2022-06-300001121404IFRS-Full：现金流量对冲成员SNY：ForwardCurrencySalesInUSDollarMember2022-06-300001121404IFRS-Full：不晚于一年成员SNY：ForwardCurrencySalesInUSDollarMemberSNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：不晚于一年成员SNY：ForwardCurrencySalesInUSDollarMember2022-06-300001121404IFRS-Full：不晚于一年成员Sny:ForwardCurrencySalesInSingaporeDollarMemberSNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：不晚于一年成员Sny:ForwardCurrencySalesInSingaporeDollarMember2022-06-300001121404IFRS-Full：不晚于一年成员SNY：AtNotionalAmount成员SNY：ForwardCurrencySalesInPoundSterlingMember2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：不晚于一年成员SNY：ForwardCurrencySalesInPoundSterlingMember2022-06-300001121404Ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberSNY：远期现货购买量美元成员SNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberIfrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberSNY：远期现货购买量美元成员2022-06-300001121404Ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberSny:ForwardCurrencyPurchasesInSingaporeDollarMemberSNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberIfrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberSny:ForwardCurrencyPurchasesInSingaporeDollarMember2022-06-300001121404IFRS-Full：不晚于一年成员SNY：AtNotionalAmount成员Sny:ForwardCurrencyPurchasesInJapaneseYenMember2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：不晚于一年成员Sny:ForwardCurrencyPurchasesInJapaneseYenMember2022-06-300001121404SNY：ForwardCurrencySalesInUSDollarMember2022-06-300001121404Sny:ForwardCurrencySalesInSingaporeDollarMember2022-06-30ISO 4217：SGD0001121404Sny:ForwardCurrencyPurchasesInUSDollarUSBondMember2022-06-300001121404Sny:ForwardCurrencyPurchasesInUSDollarUSBondMember2022-01-012022-06-300001121404Sny:ForwardCurrencyPurchasesInUSDollarIntragroupAccountMember2022-06-300001121404Sny:ForwardCurrencyPurchasesInUSDollarIntragroupAccountMember2022-01-012022-06-300001121404Sny:ForwardCurrencyPurchasesInSingaporeDollarMember2022-06-300001121404Sny:ForwardCurrencyPurchasesInSingaporeDollarMember2022-01-012022-06-300001121404Sny:InterestRateSwapsPayCapitalizedEsterReceive006Member2022-06-300001121404IFRS-Full：不晚于一年成员SNY：AtNotionalAmount成员Sny:InterestRateSwapsPayCapitalizedEsterReceive006Member2022-06-300001121404Ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberSNY：AtNotionalAmount成员Sny:InterestRateSwapsPayCapitalizedEsterReceive006Member2022-06-300001121404Ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMemberSNY：AtNotionalAmount成员Sny:InterestRateSwapsPayCapitalizedEsterReceive006Member2022-06-300001121404SNY：AtNotionalAmount成员Ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMemberSny:InterestRateSwapsPayCapitalizedEsterReceive006Member2022-06-300001121404Ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMemberSNY：AtNotionalAmount成员Sny:InterestRateSwapsPayCapitalizedEsterReceive006Member2022-06-300001121404SNY：AtNotionalAmount成员Sny:InterestRateSwapsPayCapitalizedEsterReceive006Member2022-06-300001121404IFRS-Full：AtFairValueMemberSny:InterestRateSwapsPayCapitalizedEsterReceive006Member2022-06-300001121404IFRS-Full：FairValueHedgesMemberSNY：AtNotionalAmount成员Sny:InterestRateSwapsPayCapitalizedEsterReceive006Member2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：FairValueHedgesMemberSny:InterestRateSwapsPayCapitalizedEsterReceive006Member2022-06-300001121404IFRS-Full：现金流量对冲成员SNY：AtNotionalAmount成员Sny:InterestRateSwapsPayCapitalizedEsterReceive006Member2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：现金流量对冲成员Sny:InterestRateSwapsPayCapitalizedEsterReceive006Member2022-06-300001121404IFRS-Full：现金流量对冲成员SNY：ValueOfHedgeRecognizedInEquityMemberSny:InterestRateSwapsPayCapitalizedEsterReceive006Member2022-06-300001121404Sny:InterestRateSwapsPay057ReceiveCapitalizedEsterMember2022-06-300001121404Sny:InterestRateSwapsPay057ReceiveCapitalizedEsterMemberIFRS-Full：不晚于一年成员SNY：AtNotionalAmount成员2022-06-300001121404Sny:InterestRateSwapsPay057ReceiveCapitalizedEsterMemberIfrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberSNY：AtNotionalAmount成员2022-06-300001121404Sny:InterestRateSwapsPay057ReceiveCapitalizedEsterMemberIfrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMemberSNY：AtNotionalAmount成员2022-06-300001121404Sny:InterestRateSwapsPay057ReceiveCapitalizedEsterMemberSNY：AtNotionalAmount成员Ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2022-06-300001121404Sny:InterestRateSwapsPay057ReceiveCapitalizedEsterMemberIfrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMemberSNY：AtNotionalAmount成员2022-06-300001121404Sny:InterestRateSwapsPay057ReceiveCapitalizedEsterMemberSNY：AtNotionalAmount成员2022-06-300001121404Sny:InterestRateSwapsPay057ReceiveCapitalizedEsterMemberIFRS-Full：AtFairValueMember2022-06-300001121404Sny:InterestRateSwapsPay057ReceiveCapitalizedEsterMemberIFRS-Full：FairValueHedgesMemberSNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberSny:InterestRateSwapsPay057ReceiveCapitalizedEsterMemberIFRS-Full：FairValueHedgesMember2022-06-300001121404Sny:InterestRateSwapsPay057ReceiveCapitalizedEsterMemberIFRS-Full：现金流量对冲成员SNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberSny:InterestRateSwapsPay057ReceiveCapitalizedEsterMemberIFRS-Full：现金流量对冲成员2022-06-300001121404Sny:InterestRateSwapsPay057ReceiveCapitalizedEsterMemberIFRS-Full：现金流量对冲成员SNY：ValueOfHedgeRecognizedInEquityMember2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive103MemberIFRS-Full：不晚于一年成员SNY：AtNotionalAmount成员2022-06-300001121404Ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberSny:InterestRateSwapsPayCapitalizedSOFRUSDReceive103MemberSNY：AtNotionalAmount成员2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive103MemberIfrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMemberSNY：AtNotionalAmount成员2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive103MemberSNY：AtNotionalAmount成员Ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive103MemberIfrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMemberSNY：AtNotionalAmount成员2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive103MemberSNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberSny:InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive103MemberIFRS-Full：FairValueHedgesMemberSNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberSny:InterestRateSwapsPayCapitalizedSOFRUSDReceive103MemberIFRS-Full：FairValueHedgesMember2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive103MemberIFRS-Full：现金流量对冲成员SNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberSny:InterestRateSwapsPayCapitalizedSOFRUSDReceive103MemberIFRS-Full：现金流量对冲成员2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive103MemberIFRS-Full：现金流量对冲成员SNY：ValueOfHedgeRecognizedInEquityMember2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132MemberIFRS-Full：不晚于一年成员SNY：AtNotionalAmount成员2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132MemberIfrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberSNY：AtNotionalAmount成员2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132MemberIfrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMemberSNY：AtNotionalAmount成员2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132MemberSNY：AtNotionalAmount成员Ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132MemberIfrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMemberSNY：AtNotionalAmount成员2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132MemberSNY：AtNotionalAmount成员2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132MemberIFRS-Full：AtFairValueMember2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132MemberIFRS-Full：FairValueHedgesMemberSNY：AtNotionalAmount成员2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132MemberIFRS-Full：AtFairValueMemberIFRS-Full：FairValueHedgesMember2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132MemberIFRS-Full：现金流量对冲成员SNY：AtNotionalAmount成员2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132MemberIFRS-Full：AtFairValueMemberIFRS-Full：现金流量对冲成员2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132MemberIFRS-Full：现金流量对冲成员SNY：ValueOfHedgeRecognizedInEquityMember2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedEsterReceive069Member2022-06-300001121404IFRS-Full：不晚于一年成员Sny:InterestRateSwapsPayCapitalizedEsterReceive069MemberSNY：AtNotionalAmount成员2022-06-300001121404Ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberSny:InterestRateSwapsPayCapitalizedEsterReceive069MemberSNY：AtNotionalAmount成员2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedEsterReceive069MemberIfrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMemberSNY：AtNotionalAmount成员2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedEsterReceive069MemberSNY：AtNotionalAmount成员Ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2022-06-300001121404Ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMemberSny:InterestRateSwapsPayCapitalizedEsterReceive069MemberSNY：AtNotionalAmount成员2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedEsterReceive069MemberSNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberSny:InterestRateSwapsPayCapitalizedEsterReceive069Member2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedEsterReceive069MemberIFRS-Full：FairValueHedgesMemberSNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberSny:InterestRateSwapsPayCapitalizedEsterReceive069MemberIFRS-Full：FairValueHedgesMember2022-06-300001121404IFRS-Full：现金流量对冲成员Sny:InterestRateSwapsPayCapitalizedEsterReceive069MemberSNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：现金流量对冲成员Sny:InterestRateSwapsPayCapitalizedEsterReceive069Member2022-06-300001121404IFRS-Full：现金流量对冲成员Sny:InterestRateSwapsPayCapitalizedEsterReceive069MemberSNY：ValueOfHedgeRecognizedInEquityMember2022-06-300001121404Sny:InterestRateSwapsPayCapitalizedEsterReceive092Member2022-06-300001121404IFRS-Full：不晚于一年成员SNY：AtNotionalAmount成员Sny:InterestRateSwapsPayCapitalizedEsterReceive092Member2022-06-300001121404Ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberSNY：AtNotionalAmount成员Sny:InterestRateSwapsPayCapitalizedEsterReceive092Member2022-06-300001121404Ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMemberSNY：AtNotionalAmount成员Sny:InterestRateSwapsPayCapitalizedEsterReceive092Member2022-06-300001121404SNY：AtNotionalAmount成员Sny:InterestRateSwapsPayCapitalizedEsterReceive092MemberIfrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2022-06-300001121404Ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMemberSNY：AtNotionalAmount成员Sny:InterestRateSwapsPayCapitalizedEsterReceive092Member2022-06-300001121404SNY：AtNotionalAmount成员Sny:InterestRateSwapsPayCapitalizedEsterReceive092Member2022-06-300001121404IFRS-Full：AtFairValueMemberSny:InterestRateSwapsPayCapitalizedEsterReceive092Member2022-06-300001121404IFRS-Full：FairValueHedgesMemberSNY：AtNotionalAmount成员Sny:InterestRateSwapsPayCapitalizedEsterReceive092Member2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：FairValueHedgesMemberSny:InterestRateSwapsPayCapitalizedEsterReceive092Member2022-06-300001121404IFRS-Full：现金流量对冲成员SNY：AtNotionalAmount成员Sny:InterestRateSwapsPayCapitalizedEsterReceive092Member2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：现金流量对冲成员Sny:InterestRateSwapsPayCapitalizedEsterReceive092Member2022-06-300001121404IFRS-Full：现金流量对冲成员SNY：ValueOfHedgeRecognizedInEquityMemberSny:InterestRateSwapsPayCapitalizedEsterReceive092Member2022-06-300001121404Sny:InterestRateSwapsReceiveCapitalizedEoniaPay158Member2022-06-300001121404IFRS-Full：不晚于一年成员Sny:InterestRateSwapsReceiveCapitalizedEoniaPay158MemberSNY：AtNotionalAmount成员2022-06-300001121404Ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberSny:InterestRateSwapsReceiveCapitalizedEoniaPay158MemberSNY：AtNotionalAmount成员2022-06-300001121404Sny:InterestRateSwapsReceiveCapitalizedEoniaPay158MemberIfrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMemberSNY：AtNotionalAmount成员2022-06-300001121404Sny:InterestRateSwapsReceiveCapitalizedEoniaPay158MemberSNY：AtNotionalAmount成员Ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2022-06-300001121404Ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMemberSny:InterestRateSwapsReceiveCapitalizedEoniaPay158MemberSNY：AtNotionalAmount成员2022-06-300001121404Sny:InterestRateSwapsReceiveCapitalizedEoniaPay158MemberSNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberSny:InterestRateSwapsReceiveCapitalizedEoniaPay158Member2022-06-300001121404Sny:InterestRateSwapsReceiveCapitalizedEoniaPay158MemberIFRS-Full：FairValueHedgesMemberSNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberSny:InterestRateSwapsReceiveCapitalizedEoniaPay158MemberIFRS-Full：FairValueHedgesMember2022-06-300001121404IFRS-Full：现金流量对冲成员Sny:InterestRateSwapsReceiveCapitalizedEoniaPay158MemberSNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：现金流量对冲成员Sny:InterestRateSwapsReceiveCapitalizedEoniaPay158Member2022-06-300001121404IFRS-Full：现金流量对冲成员SNY：ValueOfHedgeRecognizedInEquityMemberSny:InterestRateSwapsReceiveCapitalizedEoniaPay158Member2022-06-300001121404IFRS-Full：不晚于一年成员SNY：AtNotionalAmount成员2022-06-300001121404Ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMemberSNY：AtNotionalAmount成员2022-06-300001121404Ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMemberSNY：AtNotionalAmount成员2022-06-300001121404SNY：AtNotionalAmount成员Ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2022-06-300001121404Ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMemberSNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：FairValueHedgesMemberSNY：AtNotionalAmount成员2022-06-300001121404IFRS-Full：AtFairValueMemberIFRS-Full：FairValueHedgesMember2022-06-300001121404Sny:BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember2021-12-310001121404Sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember2021-12-310001121404Sny:ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember2021-12-310001121404Sny:ContingentConsiderationArisingFromAcquisitionOfAmunixMember2021-12-310001121404SNY：其他责任1成员2021-12-310001121404Sny:BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember2022-01-012022-06-300001121404Sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember2022-01-012022-06-300001121404Sny:ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember2022-01-012022-06-300001121404Sny:ContingentConsiderationArisingFromAcquisitionOfAmunixMember2022-01-012022-06-300001121404SNY：其他责任1成员2022-01-012022-06-300001121404Sny:BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember2022-06-300001121404Sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember2022-06-300001121404Sny:ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember2022-06-300001121404Sny:ContingentConsiderationArisingFromAcquisitionOfAmunixMember2022-06-300001121404SNY：其他责任1成员2022-06-300001121404IFRS-Full：TopOfRangeMemberSny:BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember2022-01-012022-06-300001121404Sny:ProvisionsForPensionsAndOtherPostemploymentBenefitsMember2021-12-310001121404SNY：其他长期福利拨备成员2021-12-310001121404SNY：非当前重构配置成员2021-12-310001121404IFRS-Full：杂项其他拨备成员2021-12-310001121404Sny:ProvisionsForPensionsAndOtherPostemploymentBenefitsMember2022-01-012022-06-300001121404SNY：其他长期福利拨备成员2022-01-012022-06-300001121404SNY：非当前重构配置成员2022-01-012022-06-300001121404IFRS-Full：杂项其他拨备成员2022-01-012022-06-300001121404Sny:ProvisionsForPensionsAndOtherPostemploymentBenefitsMember2022-06-300001121404SNY：其他长期福利拨备成员2022-06-300001121404SNY：非当前重构配置成员2022-06-300001121404IFRS-Full：杂项其他拨备成员2022-06-300001121404Sny:PensionsAndOtherPostEmploymentBenefitsMemberIFRS-FULL：计划资产成员2022-01-012022-06-300001121404Sny:PensionsAndOtherPostEmploymentBenefitsMemberIFRS-FULL：计划资产成员2021-01-012021-06-300001121404Sny:PensionsAndOtherPostEmploymentBenefitsMemberIFRS-FULL：计划资产成员2021-01-012021-12-310001121404Sny:PensionsAndOtherPostEmploymentBenefitsMember2022-01-012022-06-300001121404Sny:PensionsAndOtherPostEmploymentBenefitsMember2021-01-012021-06-300001121404Sny:PensionsAndOtherPostEmploymentBenefitsMember2021-01-012021-12-310001121404Ifrs-full:ActuarialAssumptionOfDiscountRatesMemberSRT：最小成员数2022-06-300001121404Ifrs-full:ActuarialAssumptionOfDiscountRatesMemberSRT：最大成员数2022-06-300001121404国家：GBIfrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMember2022-06-300001121404Ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMemberSNY：欧洲经济区成员2022-06-300001121404Ifrs-full:ActuarialAssumptionOfDiscountRatesMemberSRT：最大成员数2021-06-300001121404Ifrs-full:ActuarialAssumptionOfDiscountRatesMemberSRT：最小成员数2021-06-300001121404国家：GBIfrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMember2021-06-300001121404Ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMemberSNY：欧洲经济区成员2021-06-300001121404SNY：ExScience成员SRT：最大成员数2022-01-07SNY：分子0001121404SNY：ABLBioMembers2022-01-112022-01-110001121404SNY：ABLBioMembersSRT：最大成员数2022-01-110001121404SNY：AdageneIncMember2022-03-022022-03-020001121404SNY：AdageneIncMemberSRT：最大成员数2022-03-020001121404SNY：抗体协作协议成员SNY：Blackstone生命科学成员2022-03-152022-03-150001121404SNY：IGM BiosciencesIncMemberSRT：最大成员数2022-03-29SNY：目标0001121404SNY：生产责任成员SNY：ActionForWhichWeAreDefendantMemberSNY：ZantacProductLitigationin the US成员2022-06-300001121404SNY：生产责任成员SNY：ActionForWhichWeAreDefendantMemberSNY：DepakineProductLitigationIn FranceMember2022-05-120001121404SNY：生产责任成员SNY：ActionForWhichWeAreDefendantMemberSNY：DepakineProductLitigationIn FranceMember2022-05-122022-05-120001121404SNY：西班牙DepakineProductLitigationin成员SNY：生产责任成员SNY：ActionForWhichWeAreDefendantMember2022-03-17SNY：索赔人0001121404SNY：西班牙DepakineProductLitigationin成员SNY：生产责任成员SNY：ActionForWhichWeAreDefendantMember2022-03-172022-03-170001121404SNY：其他运营收入支出成员IFRS-Full：OtherRelatedPartiesMember2022-01-012022-06-300001121404SNY：其他运营收入支出成员IFRS-Full：OtherRelatedPartiesMember2021-01-012021-06-300001121404SNY：其他运营收入支出成员SNY：更新成员2022-01-012022-06-300001121404SNY：其他运营收入支出成员SNY：更新成员2021-01-012021-06-300001121404SNY：第一三代成员SNY：其他运营收入支出成员2021-01-012021-06-300001121404SNY：商业化相关费用成员SNY：更新成员IFRS-Full：OtherRelatedPartiesMember2022-01-012022-06-300001121404SNY：商业化相关费用成员SNY：更新成员IFRS-Full：OtherRelatedPartiesMember2021-01-012021-06-300001121404Sny:ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMemberSNY：抗体联盟成员2022-01-012022-06-300001121404Sny:ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMemberSNY：抗体联盟成员2021-01-012021-06-300001121404Sny:ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMemberSNY：抗体联盟成员2021-01-012021-12-310001121404SNY：抗体联盟成员Sny:ShareOfProfitOrLossFromCommercializationOfZaltrapMember2022-01-012022-06-300001121404SNY：抗体联盟成员Sny:ShareOfProfitOrLossFromCommercializationOfZaltrapMember2021-01-012021-06-300001121404SNY：抗体联盟成员Sny:ShareOfProfitOrLossFromCommercializationOfZaltrapMember2021-01-012021-12-310001121404SNY：抗体联盟成员SNY：商业化相关费用成员2022-01-012022-06-300001121404SNY：抗体联盟成员SNY：商业化相关费用成员2021-01-012021-06-300001121404SNY：抗体联盟成员SNY：商业化相关费用成员2021-01-012021-12-310001121404SNY：抗体联盟成员2022-01-012022-06-300001121404SNY：抗体联盟成员2021-01-012021-06-300001121404SNY：抗体联盟成员2021-01-012021-12-310001121404SNY：免疫肿瘤学联盟成员2022-01-012022-06-300001121404SNY：免疫肿瘤学联盟成员2021-01-012021-06-300001121404SNY：免疫肿瘤学联盟成员2021-01-012021-12-310001121404SNY：其他交易对手成员2022-01-012022-06-300001121404SNY：其他交易对手成员2021-01-012021-06-300001121404SNY：其他交易对手成员2021-01-012021-12-310001121404SNY：其他运营收入支出成员SNY：更新成员2021-01-012021-12-3100011214042021-07-012022-06-300001121404SNY：利率和货币衍生品成员2022-01-012022-06-300001121404SNY：利率和货币衍生品成员2021-01-012021-06-300001121404SNY：利率和货币衍生品成员2021-01-012021-12-31SNY：线段0001121404SNY：制药部门成员SRT：欧洲成员2022-01-012022-06-300001121404国家：美国SNY：制药部门成员2022-01-012022-06-300001121404SNY：其他国家/地区成员SNY：制药部门成员2022-01-012022-06-300001121404SNY：制药部门成员2022-01-012022-06-300001121404SNY：制药部门成员SRT：欧洲成员2021-01-012021-06-300001121404国家：美国SNY：制药部门成员2021-01-012021-06-300001121404SNY：其他国家/地区成员SNY：制药部门成员2021-01-012021-06-300001121404SNY：制药部门成员2021-01-012021-06-300001121404SNY：General MedicineMemberSNY：制药部门成员SRT：欧洲成员2022-01-012022-06-300001121404国家：美国SNY：General MedicineMemberSNY：制药部门成员2022-01-012022-06-300001121404SNY：其他国家/地区成员SNY：General MedicineMemberSNY：制药部门成员2022-01-012022-06-300001121404SNY：General MedicineMemberSNY：制药部门成员2022-01-012022-06-300001121404SNY：General MedicineMemberSNY：制药部门成员SRT：欧洲成员2021-01-012021-06-300001121404国家：美国SNY：General MedicineMemberSNY：制药部门成员2021-01-012021-06-300001121404SNY：其他国家/地区成员SNY：General MedicineMemberSNY：制药部门成员2021-01-012021-06-300001121404SNY：General MedicineMemberSNY：制药部门成员2021-01-012021-06-300001121404SNY：制药部门成员SNY：Lantus成员SRT：欧洲成员2022-01-012022-06-300001121404国家：美国SNY：制药部门成员SNY：Lantus成员2022-01-012022-06-300001121404SNY：其他国家/地区成员SNY：制药部门成员SNY：Lantus成员2022-01-012022-06-300001121404SNY：制药部门成员SNY：Lantus成员2022-01-012022-06-300001121404SNY：制药部门成员SNY：Lantus成员SRT：欧洲成员2021-01-012021-06-300001121404国家：美国SNY：制药部门成员SNY：Lantus成员2021-01-012021-06-300001121404SNY：其他国家/地区成员SNY：制药部门成员SNY：Lantus成员2021-01-012021-06-300001121404SNY：制药部门成员SNY：Lantus成员2021-01-012021-06-300001121404SNY：制药部门成员SRT：欧洲成员SNY：ToujeoMember2022-01-012022-06-300001121404国家：美国SNY：制药部门成员SNY：ToujeoMember2022-01-012022-06-300001121404SNY：其他国家/地区成员SNY：制药部门成员SNY：ToujeoMember2022-01-012022-06-300001121404SNY：制药部门成员SNY：ToujeoMember2022-01-012022-06-300001121404SNY：制药部门成员SRT：欧洲成员SNY：ToujeoMember2021-01-012021-06-300001121404国家：美国SNY：制药部门成员SNY：ToujeoMember2021-01-012021-06-300001121404SNY：其他国家/地区成员SNY：制药部门成员SNY：ToujeoMember2021-01-012021-06-300001121404SNY：制药部门成员SNY：ToujeoMember2021-01-012021-06-300001121404SNY：制药部门成员SRT：欧洲成员SNY：Praluent成员2022-01-012022-06-300001121404国家：美国SNY：制药部门成员SNY：Praluent成员2022-01-012022-06-300001121404SNY：其他国家/地区成员SNY：制药部门成员SNY：Praluent成员2022-01-012022-06-300001121404SNY：制药部门成员SNY：Praluent成员2022-01-012022-06-300001121404SNY：制药部门成员SRT：欧洲成员SNY：Praluent成员2021-01-012021-06-300001121404国家：美国SNY：制药部门成员SNY：Praluent成员2021-01-012021-06-300001121404SNY：其他国家/地区成员SNY：制药部门成员SNY：Praluent成员2021-01-012021-06-300001121404SNY：制药部门成员SNY：Praluent成员2021-01-012021-06-300001121404SNY：制药部门成员SRT：欧洲成员SNY：多个成员2022-01-012022-06-300001121404国家：美国SNY：制药部门成员SNY：多个成员2022-01-012022-06-300001121404SNY：其他国家/地区成员SNY：制药部门成员SNY：多个成员2022-01-012022-06-300001121404SNY：制药部门成员SNY：多个成员2022-01-012022-06-300001121404SNY：制药部门成员SRT：欧洲成员SNY：多个成员2021-01-012021-06-300001121404国家：美国SNY：制药部门成员SNY：多个成员2021-01-012021-06-300001121404SNY：其他国家/地区成员SNY：制药部门成员SNY：多个成员2021-01-012021-06-300001121404SNY：制药部门成员SNY：多个成员2021-01-012021-06-300001121404SNY：制药部门成员SRT：欧洲成员SNY：LovenoxMember2022-01-012022-06-300001121404国家：美国SNY：制药部门成员SNY：LovenoxMember2022-01-012022-06-300001121404SNY：其他国家/地区成员SNY：制药部门成员SNY：LovenoxMember2022-01-012022-06-300001121404SNY：制药部门成员SNY：LovenoxMember2022-01-012022-06-300001121404SNY：制药部门成员SRT：欧洲成员SNY：LovenoxMember2021-01-012021-06-300001121404国家：美国SNY：制药部门成员SNY：LovenoxMember2021-01-012021-06-300001121404SNY：其他国家/地区成员SNY：制药部门成员SNY：LovenoxMember2021-01-012021-06-300001121404SNY：制药部门成员SNY：LovenoxMember2021-01-012021-06-300001121404SNY：PlavixMemberSNY：制药部门成员SRT：欧洲成员2022-01-012022-06-300001121404国家：美国SNY：PlavixMemberSNY：制药部门成员2022-01-012022-06-300001121404SNY：其他国家/地区成员SNY：PlavixMemberSNY：制药部门成员2022-01-012022-06-300001121404SNY：PlavixMemberSNY：制药部门成员2022-01-012022-06-300001121404SNY：PlavixMemberSNY：制药部门成员SRT：欧洲成员2021-01-012021-06-300001121404国家：美国SNY：PlavixMemberSNY：制药部门成员2021-01-012021-06-300001121404SNY：其他国家/地区成员SNY：PlavixMemberSNY：制药部门成员2021-01-012021-06-300001121404SNY：PlavixMemberSNY：制药部门成员2021-01-012021-06-300001121404SNY：制药部门成员SRT：欧洲成员SNY：胸腺球蛋白成员2022-01-012022-06-300001121404国家：美国SNY：制药部门成员SNY：胸腺球蛋白成员2022-01-012022-06-300001121404SNY：其他国家/地区成员SNY：制药部门成员SNY：胸腺球蛋白成员2022-01-012022-06-300001121404SNY：制药部门成员SNY：胸腺球蛋白成员2022-01-012022-06-300001121404SNY：制药部门成员SRT：欧洲成员SNY：胸腺球蛋白成员2021-01-012021-06-300001121404国家：美国SNY：制药部门成员SNY：胸腺球蛋白成员2021-01-012021-06-300001121404SNY：其他国家/地区成员SNY：制药部门成员SNY：胸腺球蛋白成员2021-01-012021-06-300001121404SNY：制药部门成员SNY：胸腺球蛋白成员2021-01-012021-06-300001121404SNY：制药部门成员SRT：欧洲成员SNY：行业销售成员2022-01-012022-06-300001121404国家：美国SNY：制药部门成员SNY：行业销售成员2022-01-012022-06-300001121404SNY：其他国家/地区成员SNY：制药部门成员SNY：行业销售成员2022-01-012022-06-300001121404SNY：制药部门成员SNY：行业销售成员2022-01-012022-06-300001121404SNY：制药部门成员SRT：欧洲成员SNY：行业销售成员2021-01-012021-06-300001121404国家：美国SNY：制药部门成员SNY：行业销售成员2021-01-012021-06-300001121404SNY：其他国家/地区成员SNY：制药部门成员SNY：行业销售成员2021-01-012021-06-300001121404SNY：制药部门成员SNY：行业销售成员2021-01-012021-06-300001121404SNY：制药部门成员SRT：欧洲成员SNY：Special CareMember2022-01-012022-06-300001121404国家：美国SNY：制药部门成员SNY：Special CareMember2022-01-012022-06-300001121404SNY：其他国家/地区成员SNY：制药部门成员SNY：Special CareMember2022-01-012022-06-300001121404SNY：制药部门成员SNY：Special CareMember2022-01-012022-06-300001121404SNY：制药部门成员SRT：欧洲成员SNY：Special CareMember2021-01-012021-06-300001121404国家：美国SNY：制药部门成员SNY：Special CareMember2021-01-012021-06-300001121404SNY：其他国家/地区成员SNY：制药部门成员SNY：Special CareMember2021-01-012021-06-300001121404SNY：制药部门成员SNY：Special CareMember2021-01-012021-06-300001121404SNY：制药部门成员SRT：欧洲成员纽约：8月bagio成员2022-01-012022-06-300001121404国家：美国SNY：制药部门成员纽约：8月bagio成员2022-01-012022-06-300001121404SNY：其他国家/地区成员SNY：制药部门成员纽约：8月bagio成员2022-01-012022-06-300001121404SNY：制药部门成员纽约：8月bagio成员2022-01-012022-06-300001121404SNY：制药部门成员SRT：欧洲成员纽约：8月bagio成员2021-01-012021-06-300001121404国家：美国SNY：制药部门成员纽约：8月bagio成员2021-01-012021-06-300001121404SNY：其他国家/地区成员SNY：制药部门成员纽约：8月bagio成员2021-01-012021-06-300001121404SNY：制药部门成员纽约：8月bagio成员2021-01-012021-06-300001121404SNY：Cerezyme成员SNY：制药部门成员SRT：欧洲成员2022-01-012022-06-300001121404国家：美国SNY：Cerezyme成员SNY：制药部门成员2022-01-012022-06-300001121404SNY：其他国家/地区成员SNY：Cerezyme成员SNY：制药部门成员2022-01-012022-06-300001121404SNY：Cerezyme成员SNY：制药部门成员2022-01-012022-06-300001121404SNY：Cerezyme成员SNY：制药部门成员SRT：欧洲成员2021-01-012021-06-300001121404国家：美国SNY：Cerezyme成员SNY：制药部门成员2021-01-012021-06-300001121404SNY：其他国家/地区成员SNY：Cerezyme成员SNY：制药部门成员2021-01-012021-06-300001121404SNY：Cerezyme成员SNY：制药部门成员2021-01-012021-06-300001121404SNY：制药部门成员SRT：欧洲成员SNY：MyozymeOrLumizymeMember2022-01-012022-06-300001121404国家：美国SNY：制药部门成员SNY：MyozymeOrLumizymeMember2022-01-012022-06-300001121404SNY：其他国家/地区成员SNY：制药部门成员SNY：MyozymeOrLumizymeMember2022-01-012022-06-300001121404SNY：制药部门成员SNY：MyozymeOrLumizymeMember2022-01-012022-06-300001121404SNY：制药部门成员SRT：欧洲成员SNY：MyozymeOrLumizymeMember2021-01-012021-06-300001121404国家：美国SNY：制药部门成员SNY：MyozymeOrLumizymeMember2021-01-012021-06-300001121404SNY：其他国家/地区成员SNY：制药部门成员SNY：MyozymeOrLumizymeMember2021-01-012021-06-300001121404SNY：制药部门成员SNY：MyozymeOrLumizymeMember2021-01-012021-06-300001121404SNY：制药部门成员SRT：欧洲成员SNY：Fradzyme成员2022-01-012022-06-300001121404国家：美国SNY：制药部门成员SNY：Fradzyme成员2022-01-012022-06-300001121404SNY：其他国家/地区成员SNY：制药部门成员SNY：Fradzyme成员2022-01-012022-06-300001121404SNY：制药部门成员SNY：Fradzyme成员2022-01-012022-06-300001121404SNY：制药部门成员SRT：欧洲成员SNY：Fradzyme成员2021-01-012021-06-300001121404国家：美国SNY：制药部门成员SNY：Fradzyme成员2021-01-012021-06-300001121404SNY：其他国家/地区成员SNY：制药部门成员SNY：Fradzyme成员2021-01-012021-06-300001121404SNY：制药部门成员SNY：Fradzyme成员2021-01-012021-06-300001121404SNY：制药部门成员SRT：欧洲成员SNY：ELoctateMember2022-01-012022-06-300001121404国家：美国SNY：制药部门成员SNY：ELoctateMember2022-01-012022-06-300001121404SNY：其他国家/地区成员SNY：制药部门成员SNY：ELoctateMember2022-01-012022-06-300001121404SNY：制药部门成员SNY：ELoctateMember2022-01-012022-06-300001121404SNY：制药部门成员SRT：欧洲成员SNY：ELoctateMember2021-01-012021-06-300001121404国家：美国SNY：制药部门成员SNY：ELoctateMember2021-01-012021-06-300001121404SNY：其他国家/地区成员SNY：制药部门成员SNY：ELoctateMember2021-01-012021-06-300001121404SNY：制药部门成员SNY：ELoctateMember2021-01-012021-06-300001121404SNY：制药部门成员SRT：欧洲成员纽约：杰夫塔纳成员2022-01-012022-06-300001121404国家：美国SNY：制药部门成员纽约：杰夫塔纳成员2022-01-012022-06-300001121404SNY：其他国家/地区成员SNY：制药部门成员纽约：杰夫塔纳成员2022-01-012022-06-300001121404SNY：制药部门成员纽约：杰夫塔纳成员2022-01-012022-06-300001121404SNY：制药部门成员SRT：欧洲成员纽约：杰夫塔纳成员2021-01-012021-06-300001121404国家：美国SNY：制药部门成员纽约：杰夫塔纳成员2021-01-012021-06-300001121404SNY：其他国家/地区成员SNY：制药部门成员纽约：杰夫塔纳成员2021-01-012021-06-300001121404SNY：制药部门成员纽约：杰夫塔纳成员2021-01-012021-06-300001121404纽约：DupixentMemberSNY：制药部门成员SRT：欧洲成员2022-01-012022-06-300001121404国家：美国纽约：DupixentMemberSNY：制药部门成员2022-01-012022-06-300001121404SNY：其他国家/地区成员纽约：DupixentMemberSNY：制药部门成员2022-01-012022-06-300001121404纽约：DupixentMemberSNY：制药部门成员2022-01-012022-06-300001121404纽约：DupixentMemberSNY：制药部门成员SRT：欧洲成员2021-01-012021-06-300001121404国家：美国纽约：DupixentMemberSNY：制药部门成员2021-01-012021-06-300001121404SNY：其他国家/地区成员纽约：DupixentMemberSNY：制药部门成员2021-01-012021-06-300001121404纽约：DupixentMemberSNY：制药部门成员2021-01-012021-06-300001121404SNY：疫苗部门成员SRT：欧洲成员2022-01-012022-06-300001121404国家：美国SNY：疫苗部门成员2022-01-012022-06-300001121404SNY：其他国家/地区成员SNY：疫苗部门成员2022-01-012022-06-300001121404SNY：疫苗部门成员2022-01-012022-06-300001121404SNY：疫苗部门成员SRT：欧洲成员2021-01-012021-06-300001121404国家：美国SNY：疫苗部门成员2021-01-012021-06-300001121404SNY：其他国家/地区成员SNY：疫苗部门成员2021-01-012021-06-300001121404SNY：疫苗部门成员2021-01-012021-06-300001121404SNY：疫苗部门成员SRT：欧洲成员SNY：脊髓灰质炎疫苗成员2022-01-012022-06-300001121404国家：美国SNY：疫苗部门成员SNY：脊髓灰质炎疫苗成员2022-01-012022-06-300001121404SNY：其他国家/地区成员SNY：疫苗部门成员SNY：脊髓灰质炎疫苗成员2022-01-012022-06-300001121404SNY：疫苗部门成员SNY：脊髓灰质炎疫苗成员2022-01-012022-06-300001121404SNY：疫苗部门成员SRT：欧洲成员SNY：脊髓灰质炎疫苗成员2021-01-012021-06-300001121404国家：美国SNY：疫苗部门成员SNY：脊髓灰质炎疫苗成员2021-01-012021-06-300001121404SNY：其他国家/地区成员SNY：疫苗部门成员SNY：脊髓灰质炎疫苗成员2021-01-012021-06-300001121404SNY：疫苗部门成员SNY：脊髓灰质炎疫苗成员2021-01-012021-06-300001121404SNY：疫苗部门成员SRT：欧洲成员SNY：流感疫苗成员2022-01-012022-06-300001121404国家：美国SNY：疫苗部门成员SNY：流感疫苗成员2022-01-012022-06-300001121404SNY：其他国家/地区成员SNY：疫苗部门成员SNY：流感疫苗成员2022-01-012022-06-300001121404SNY：疫苗部门成员SNY：流感疫苗成员2022-01-012022-06-300001121404SNY：疫苗部门成员SRT：欧洲成员SNY：流感疫苗成员2021-01-012021-06-300001121404国家：美国SNY：疫苗部门成员SNY：流感疫苗成员2021-01-012021-06-300001121404SNY：其他国家/地区成员SNY：疫苗部门成员SNY：流感疫苗成员2021-01-012021-06-300001121404SNY：疫苗部门成员SNY：流感疫苗成员2021-01-012021-06-300001121404SRT：欧洲成员SNY：Consumer Healthcare细分市场成员2022-01-012022-06-300001121404国家：美国SNY：Consumer Healthcare细分市场成员2022-01-012022-06-300001121404SNY：其他国家/地区成员SNY：Consumer Healthcare细分市场成员2022-01-012022-06-300001121404SNY：Consumer Healthcare细分市场成员2022-01-012022-06-300001121404SRT：欧洲成员SNY：Consumer Healthcare细分市场成员2021-01-012021-06-300001121404国家：美国SNY：Consumer Healthcare细分市场成员2021-01-012021-06-300001121404SNY：其他国家/地区成员SNY：Consumer Healthcare细分市场成员2021-01-012021-06-300001121404SNY：Consumer Healthcare细分市场成员2021-01-012021-06-300001121404SNY：所有成员SRT：欧洲成员SNY：Consumer Healthcare细分市场成员2022-01-012022-06-300001121404国家：美国SNY：所有成员SNY：Consumer Healthcare细分市场成员2022-01-012022-06-300001121404SNY：其他国家/地区成员SNY：所有成员SNY：Consumer Healthcare细分市场成员2022-01-012022-06-300001121404SNY：所有成员SNY：Consumer Healthcare细分市场成员2022-01-012022-06-300001121404SNY：所有成员SRT：欧洲成员SNY：Consumer Healthcare细分市场成员2021-01-012021-06-300001121404国家：美国SNY：所有成员SNY：Consumer Healthcare细分市场成员2021-01-012021-06-300001121404SNY：其他国家/地区成员SNY：所有成员SNY：Consumer Healthcare细分市场成员2021-01-012021-06-300001121404SNY：所有成员SNY：Consumer Healthcare细分市场成员2021-01-012021-06-300001121404SRT：欧洲成员SNY：PainCareMemberSNY：Consumer Healthcare细分市场成员2022-01-012022-06-300001121404国家：美国SNY：PainCareMemberSNY：Consumer Healthcare细分市场成员2022-01-012022-06-300001121404SNY：其他国家/地区成员SNY：PainCareMemberSNY：Consumer Healthcare细分市场成员2022-01-012022-06-300001121404SNY：PainCareMemberSNY：Consumer Healthcare细分市场成员2022-01-012022-06-300001121404SRT：欧洲成员SNY：PainCareMemberSNY：Consumer Healthcare细分市场成员2021-01-012021-06-300001121404国家：美国SNY：PainCareMemberSNY：Consumer Healthcare细分市场成员2021-01-012021-06-300001121404SNY：其他国家/地区成员SNY：PainCareMemberSNY：Consumer Healthcare细分市场成员2021-01-012021-06-300001121404SNY：PainCareMemberSNY：Consumer Healthcare细分市场成员2021-01-012021-06-300001121404SNY：消化健康成员SRT：欧洲成员SNY：Consumer Healthcare细分市场成员2022-01-012022-06-300001121404国家：美国SNY：消化健康成员SNY：Consumer Healthcare细分市场成员2022-01-012022-06-300001121404SNY：其他国家/地区成员SNY：消化健康成员SNY：Consumer Healthcare细分市场成员2022-01-012022-06-300001121404SNY：消化健康成员SNY：Consumer Healthcare细分市场成员2022-01-012022-06-300001121404SNY：消化健康成员SRT：欧洲成员SNY：Consumer Healthcare细分市场成员2021-01-012021-06-300001121404国家：美国SNY：消化健康成员SNY：Consumer Healthcare细分市场成员2021-01-012021-06-300001121404SNY：其他国家/地区成员SNY：消化健康成员SNY：Consumer Healthcare细分市场成员2021-01-012021-06-300001121404SNY：消化健康成员SNY：Consumer Healthcare细分市场成员2021-01-012021-06-300001121404SRT：欧洲成员2022-01-012022-06-300001121404国家：美国2022-01-012022-06-300001121404SNY：其他国家/地区成员2022-01-012022-06-300001121404SRT：欧洲成员2021-01-012021-06-300001121404国家：美国2021-01-012021-06-300001121404SNY：其他国家/地区成员2021-01-012021-06-300001121404IFRS-Full：所有其他部门成员2022-01-012022-06-300001121404IFRS-Full：可报告部门成员2022-01-012022-06-300001121404IFRS-Full：所有其他部门成员2021-01-012021-06-300001121404IFRS-Full：可报告部门成员2021-01-012021-06-300001121404SNY：制药部门成员2021-01-012021-12-310001121404SNY：疫苗部门成员2021-01-012021-12-310001121404SNY：Consumer Healthcare细分市场成员2021-01-012021-12-310001121404IFRS-Full：所有其他部门成员2021-01-012021-12-310001121404IFRS-Full：可报告部门成员2021-01-012021-12-310001121404IFRS-Full：运营部门成员2022-01-012022-06-300001121404IFRS-Full：运营部门成员2021-01-012021-06-300001121404IFRS-Full：运营部门成员2021-01-012021-12-310001121404IFRS-FULL：材料对账项目成员2022-01-012022-06-300001121404IFRS-FULL：材料对账项目成员2021-01-012021-06-300001121404IFRS-FULL：材料对账项目成员2021-01-012021-12-310001121404SNY：制药公司成员2022-06-300001121404SNY：疫苗成员2022-06-300001121404SNY：Consumer Healthcare细分市场成员2022-06-300001121404IFRS-Full：可报告部门成员2022-06-300001121404SNY：制药公司成员2021-06-300001121404SNY：疫苗成员2021-06-300001121404SNY：Consumer Healthcare细分市场成员2021-06-300001121404IFRS-Full：可报告部门成员2021-06-300001121404SNY：制药公司成员2021-01-012021-06-300001121404SNY：疫苗成员2021-01-012021-06-300001121404SNY：制药公司成员2021-12-310001121404SNY：疫苗成员2021-12-310001121404SNY：Consumer Healthcare细分市场成员2021-12-310001121404IFRS-Full：可报告部门成员2021-12-310001121404SNY：可报告的地理区域成员2022-01-012022-06-300001121404国家：法国2022-01-012022-06-300001121404SRT：北美成员2022-01-012022-06-300001121404Sny:OtherCountriesExcludingEuropeAndNorthAmericaMember2022-01-012022-06-300001121404SNY：可报告的地理区域成员2022-06-300001121404SRT：欧洲成员2022-06-300001121404国家：法国2022-06-300001121404SRT：北美成员2022-06-300001121404国家：美国2022-06-300001121404Sny:OtherCountriesExcludingEuropeAndNorthAmericaMember2022-06-300001121404SNY：可报告的地理区域成员2021-01-012021-06-300001121404国家：法国2021-01-012021-06-300001121404SRT：北美成员2021-01-012021-06-300001121404Sny:OtherCountriesExcludingEuropeAndNorthAmericaMember2021-01-012021-06-300001121404SNY：可报告的地理区域成员2021-06-300001121404SRT：欧洲成员2021-06-300001121404国家：法国2021-06-300001121404SRT：北美成员2021-06-300001121404国家：美国2021-06-300001121404Sny:OtherCountriesExcludingEuropeAndNorthAmericaMember2021-06-300001121404SNY：可报告的地理区域成员2021-01-012021-12-310001121404SRT：欧洲成员2021-01-012021-12-310001121404国家：法国2021-01-012021-12-310001121404SRT：北美成员2021-01-012021-12-310001121404国家：美国2021-01-012021-12-310001121404Sny:OtherCountriesExcludingEuropeAndNorthAmericaMember2021-01-012021-12-310001121404SNY：可报告的地理区域成员2021-12-310001121404SRT：欧洲成员2021-12-310001121404国家：法国2021-12-310001121404SRT：北美成员2021-12-310001121404国家：美国2021-12-310001121404Sny:OtherCountriesExcludingEuropeAndNorthAmericaMember2021-12-310001121404SNY：CertainWholesAlersInTheUnitedStates成员2022-01-012022-06-300001121404SNY：客户一号成员2022-01-012022-06-300001121404SNY：客户两个成员2022-01-012022-06-300001121404SNY：客户三人2022-01-012022-06-300001121404SNY：客户一号成员2021-01-012021-06-300001121404SNY：客户两个成员2021-01-012021-06-300001121404SNY：客户三人2021-01-012021-06-30 美国
美国证券交易委员会
华盛顿特区，20549
表格6-K
外国私人发行人报告
根据规则第13a-16或15d-16
根据1934年的《证券交易法》
2022年7月
委托公文编号：001-31368
赛诺菲
(注册人姓名英文译本)
法国巴黎75008号，法国博埃蒂街54号
(主要执行办公室地址)
用复选标记表示注册人是否在封面表格20-F或表格40-F下提交或将提交年度报告。
Form 20-F ☒ Form 40-F ☐
用复选标记表示注册人是否按照S-T规则第101(B)(1)条所允许的纸质形式提交表格6-K：☐
用复选标记表示注册人是否按照S-T规则第101(B)(7)条所允许的纸质形式提交表格6-K：☐
通过勾选标记表示注册人是否也根据1934年《证券交易法》第12g3-2(B)条向委员会提供了本表格中所包含的信息。
Yes ☐ No ☒
如“是”，请在下方注明根据第12g3-2(B)条分配给注册人的档案编号：82-
2022年7月，赛诺菲发布了作为附件99.1和99.2的财务报表和半年管理报告，在此引用作为参考。
2022年半年财务报告
目录表
| | | | | | | | | | | |
| 1. | 简明半年合并财务报表 | 2 |
| 合并资产负债表--资产 | 2 |
| 综合资产负债表--股东权益和负债 | 3 |
| 合并损益表 | 4 |
| 综合全面收益表 | 5 |
| 合并权益变动表 | 6 |
| 合并现金流量表 | 9 |
| 截至2022年6月30日的简明半年合并财务报表附注 | 11 |
| | 引言 | 11 |
| | A/编制半年财务报表和会计政策的依据 | 11 |
| | B/2022年上半年的重要信息 | 15 |
| | C/2022年6月30日之后的事件 | 39 |
| 2 | 半年管理报告 | 40 |
| | A/2022年上半年的重大事件 | 40 |
| | B/实施企业社会责任战略的进展情况 | 44 |
| | C/2022年6月30日之后的事件 | 48 |
| | D/2022年上半年合并财务报表 | 49 |
| | E/风险因素和关联方交易 | 66 |
| | F/Outlook | 67 |
| | G/附录-研究和开发管道 | 69 |
| 3 | 法定核数师报告 | 72 |
| 4 | 核证员责任书--半年财务报告 | 73 |
展品清单
| | | | | | | | |
| 证物编号： | | 描述 |
| | |
| 附件99.1 | 2022年简明半年合并财务报表 | |
| 展品99.2 | 2022年半年管理报告、法定审计师报告和责任说明 | |
展品索引
| | | | | | | | |
| 证物编号： | | 描述 |
| | |
| 附件99.1 | 2022年简明半年合并财务报表 | |
| 展品99.2 | 2022年半年管理报告、法定审计师报告和责任说明 | |
签名
根据1934年《证券交易法》的要求，注册人已正式促使本报告由正式授权的签署人代表其签署。
| | | | | | | | | | | | | | | | | | | | |
| | | | | | |
日期：2022年7月28日 | | | | | | 赛诺菲 |
| | | | | | |
| | | | 发信人： | | /s/亚历山德拉·罗杰 |
| | | | 姓名： | | 亚历山德拉·罗杰 |
| | | | 标题： | | 证券法和资本市场部主管 |